Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX15 | P16050 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.53 |
| ▸ | MALT1 | Q9UDY8 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.43 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30074638 | 0.99 | ALOX15 (0.53) | ALOX15POLBMALT1NPC1RAB9A | |
| SCHEMBL30074560 | 0.97 | ALOX15 (0.56) | ALOX15POLBMALT1NPC1RAB9A | |
| SCHEMBL30074608 | 0.90 | ALOX15 (0.48) | ALOX15POLBMALT1NPC1RAB9A | |
| SCHEMBL21531037 | 0.84 | ALOX15 (0.54) | ALOX15POLBMALT1NPC1RAB9A | |
| SCHEMBL30074568 | 0.84 | ALOX15 (0.54) | ALOX15POLBMALT1NPC1RAB9A | |
| SCHEMBL30074637 | 0.84 | ALOX15 (0.54) | ALOX15POLBMALT1NPC1RAB9A | |
| SCHEMBL21531022 | 0.84 | KDM4E (0.55) | ALOX15POLBMALT1NPC1RAB9A | |
| SCHEMBL30074585 | 0.83 | ALOX15 (0.53) | ALOX15POLBMALT1NPC1RAB9A | |
| SCHEMBL30074649 | 0.83 | ALOX15 (0.53) | ALOX15POLBMALT1NPC1RAB9A | |
| SCHEMBL30074623 | 0.83 | ALOX15 (0.53) | ALOX15POLBMALT1NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11504439-B2 | Radioactive compound for diagnosis of malignant melanoma and use thereof | INDUSTRY FOUNDATION OF CHONNAM NATIONAL UNIVERSITY (KR) | 2022-11-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11504439-B2 | Radioactive compound for diagnosis of malignant melanoma and use thereof | MITF, BRAF, MEN1 | ALOX15 3399/4885POLB 3939/4885MALT1 776/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.